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Supplementary Figures 
 
 
Supplementary Figure 1: Median duration of infection in resistant and susceptible 
individuals. 
The median duration of infection in the cohort was 2 weeks. Individuals were dichotomised 
around the median according to their median duration of infection (2 weeks) into resistant (≤ 
2 weeks) and susceptible (> 2 weeks). Red lines indicate the median. The whiskers were 
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calculated by adding 1.5 x IQR to the 75th percentile and subtracting 1.5 x IQR from the 25th 
percentile. Dots are outliers. 
 
Supplementary Figure 2: Maximum likelihood reconstruction of the whole-genome 
phylogeny of 150 ocular Ct sequences. 
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Maximum likelihood reconstruction of the whole-genome phylogeny of 150 ocular Ct 
sequences from Asia (purple), Bijagós Islands (black), North Africa (green), Solomon Islands 
(yellow), Tanzania (blue), The Gambia (red) and USA (orange). Ct sequences were mapped 
to Ct A/HAR-13 using SAMtools80. Phylogenies were computed with RAxML from a 
variable sites alignment using a GTR+gamma model and are midpoint rooted. The scale bar 
indicates evolutionary distance.   
Supplementary Tables 
Supplementary Table 1: Predicted and experimentally determined expression stage and 
localisation of susceptibility-associated antigens.  
ID PREDICTED 
LOCALISATION 
PEAK 
EXPRESSION 
(HPI) 
LOCALISATION (BY 
MICROSCOPY OR 
IMMUNOBLOTTING 
EXPRESSION (BY 
RT-qPCR OR 
MICROSCOPY 
[HPI]) 
CT_017 Cytoplasmic 40 Outer membrane1 11 
CT_021 Cytoplasmic 40   
CT_023 Secreted 40   
CT_051 Cytoplasmic 40 Inclusion lumen2  
CT_073 Secreted 24   
CT_078 Secreted 16   
CT_089 Cytoplasmic 40 Secreted3  
CT_097 Secreted 24   
CT_106 Cytoplasmic 24   
CT_118 Cytoplasmic 3-8 Inclusion membrane4 124 
CT_119 Secreted 24 Inclusion membrane4 204 
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CT_123 Inner membrane 24   
CT_142 Cytoplasmic 24 Inclusion lumen5  
CT_168 Secreted 40   
CT_181 Cytoplasmic 24   
CT_223 Secreted 40 Inclusion membrane6 206 
CT_228 Inner membrane 3-8 Inclusion membrane7 67 
CT_237 Inner membrane 40   
CT_284 Cytoplasmic 40   
CT_316 Cytoplasmic 24   
CT_381 Cytoplasmic 40   
CT_494 Secreted 40   
CT_502 Inner membrane 40   
CT_541 Cytoplasmic 40 Outer membrane8  
CT_545 Periplasmic 40   
CT_570 Cytoplasmic 40   
CT_579 Inner membrane 40 Outer membrane9  
CT_584 Secreted 40 Secreted10  
CT_592 Cytoplasmic 40   
CT_642 Periplasmic 16   
CT_664 Inner membrane 40   
CT_668 Cytoplasmic 40 Secreted11  
CT_694 Secreted 40 Secreted12 612 
CT_695 NA 24 Secreted10  
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CT_703 Cytoplasmic 24   
CT_728 Cytoplasmic 24 Cytoplasmic13 1213 
CT_764 Inner membrane 24   
CT_795 Inner membrane 16 Secreted14  
CT_806 Inner membrane 40   
CT_813 Periplasmic 16 Inclusion membrane4 244 
CT_841 Cytoplasmic 40   
CT_875 Inner membrane 40 Secreted15 215 
Predicted localisations were defined using LocTree, Cello and psortB. Peak expression was 
defined from Belland et al16. Experimental localisation and RT-qPCR/microscopic expression 
data were determined using a PubMed literature search with three terms; “CT_xxx”, 
“CTA_xxxx” and “Chlamydia trachomatis”. 
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Supplementary Table 2: Predicted and experimentally determined expression stage and, localisation, and experimentally determined 
immunogenicity and function of genes with evidence of selection. 
ID PREDICTED 
LOCALISATION 
PEAK 
EXPRESSION 
(HPI) 
IMMUNOGENIC FUNCTION LOCALISATION (BY 
MICROSCOPY OR 
IMMUNOBLOTTING 
EXPRESSION (BY RT-qPCR  
OR MICROSCOPY [HPI]) 
CT_005 Inner Membrane 16 No Unknown Inclusion membrane4 424 
CT_033 Cytoplasmic 16 No Exodeoxyribonuclease    
CT_046 Extracellular 40 No Histone-like protein   
CT_048 Cytoplasmic 24 No Methyltransferase   
CT_049 Extracellular 40 No Unknown Inclusion lumen2 482 
CT_050 Extracellular 40 No Unknown Inclusion lumen2 482 
CT_053 Cytoplasmic 24 No Unknown Secreted17 2017 
CT_082 Extracellular 24 Yes Unknown Secreted10 110 
CT_105 Extracellular 24 No Unknown Secreted11 211 
CT_116 Extracellular 3-8 Yes Retromer recruitment Inclusion membrane18 218 
CT_141 Cytoplasmic 40 No Translocase   
CT_147 Cytoplasmic 3-8 Yes Endosome 
interactions 
Inclusion membrane4 24 
CT_154 Cytoplasmic 24 No Phospholipase D   
CT_157 Cytoplasmic 40 Yes Phospholipase D   
CT_159 Extracellular 40 No Phospholipase D   
CT_223 Inner Membrane 40 Yes Microtubule 
interactions 
Inclusion membrane6 206 
CT_228 Inner Membrane 3-8 Yes Cell exit regulation Inclusion membrane7 67 
CT_229 Extracellular 3-8 Yes Rab recruitment Inclusion membrane19 219 
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CT_249 Extracellular 16 No Unknown Inclusion membrane4 24 
CT_288 Inner Membrane 3-8 Yes Unknown Inclusion membrane4 434 
CT_359 Inner Membrane 40 Yes Unknown   
CT_386 Cytoplasmic 40 No Unknown   
CT_394 Cytoplasmic 40 No Transcription 
repressor 
  
CT_396 Cytoplasmic 16 Yes Chaperone Outer membrane9  
CT_414 Extracellular 24 Yes Adhesion Outer membrane20 2420 
CT_442 Outer Membrane 24 Yes Unknown Inclusion membrane4 424 
CT_456 Extracellular 40 Yes Cell entry/actin 
reorganisation 
Outer membrane21 121 
CT_539 Cytoplasmic 24 No Thioredoxin Periplasmic22  
CT_621 Extracellular 40 Yes Unknown Secreted23 1623 
CT_622 Cytoplasmic 24 No Unknown Secreted24 624 
CT_624 Inner Membrane 40 No Lipid II flippase   
CT_626 Cytoplasmic 40 No Protein synthesis   
CT_636 Cytoplasmic 24 No Transcription   
CT_641 Inner Membrane 40 No Membrane efflux   
CT_651 Cytoplasmic 40 No Unknown   
CT_674 Outer Membrane 40 No Type-3 secretion   
CT_680 Cytoplasmic 40 No Protein synthesis   
CT_681 Outer Membrane 24 Yes Adhesion Outer membrane25 244 
CT_683 Cytoplasmic 40 No Unknown   
CT_686 Cytoplasmic 40 No Electron transfer   
CT_688 Cytoplasmic 40 No Cell division   
CT_694 Cytoplasmic 40 Yes Actin reorganisation Secreted12 612 
CT_818 Inner Membrane 40 No Tyrosine transport   
CT_837 Cytoplasmic 40 No Unknown   
CT_845 Cytoplasmic 24 No Unknown   
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CT_859 Cytoplasmic 40 No Cellular metabolism   
CT_868 Extracellular 40 No Deubiquitination Secreted26 4826 
CT_872 Extracellular 40 Yes Adhesion Outer membrane9  
Predicted localisations were defined using LocTree, Cello and psortB. Peak expression was defined from Belland et al16. Experimental 
localisation and RT-qPCR/microscopic expression data were determined using a PubMed literature search with three terms; “CT_xxx”, 
“CTA_xxxx” and “Chlamydia trachomatis”. Immunogenicity and function were manually assigned from PubMed literature searches.
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Supplementary Table 3: Evidence of selection in immune targets from screening of the Ct-proteome micro-array. 
Genes are ordered by position in the Ct D/UW3 genome. The number of sliding windows with significant evidence of selection in the respective 
gene is indicated by ‘Fay and Wu’s H SW’ and ‘Tajima’s D SW’. Genes which fall within the three regions identified as under positive selection 
using the top 1 % of SNPs are indicated by ‘iHS window’. Genes with significant evidence of selection are highlighted (light red). 
ID NUMBER OF 
SNPS 
THETA TAJIMA’S 
D 
TAJIMA’S D 
SW 
FAY AND WU’S 
H 
FAY AND WU’S H 
SW 
IHS 
WINDOW  
CT017 8 0.001 -1.78  0.12  N 
CT021 8 0.002 -1.16  0.37  N 
CT023 8 0.001 -0.61  0.03 14 N 
CT051 11 0.001 -1.43  0.30  Y 
CT073 7 0.001 -1.24  -0.66 14 Y 
CT078 4 0.001 -1.13  -2.72  N 
CT089 7 0.001 -1.27  0.29  N 
CT097 5 0.001 -0.86  -2.77 7 N 
CT106 5 0.001 -1.74  0.49  N 
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CT118 4 0.002 -0.12  0.18 19 N 
CT119 1 < 0.001 -1.04  0.57  N 
CT123 2 0.001 -1.31  0.02  N 
CT142 4 0.001 -1.77  0.06  N 
CT168 4 0.002 -1.73  0.09  N 
CT181 3 0.001 -1.61  0.10  N 
CT223 3 0.001 -0.81  0.07  N 
CT228 8 0.003 0.069  -1.18  N 
CT237 3 0.001 -1.62  -1.30  N 
CT284 6 0.001 -1.58  0.07 6 N 
CT316 1 < 0.001 -1.03  -3.09  N 
CT381 0 0.000 NA  0.02  N 
CT494 5 0.001 -1.86  0.00  Y 
CT502 1 < 0.001 -1.03  0.13  Y 
CT541 2 0.001 -0.11  0.02  Y 
CT545 9 < 0.001 -1.82  0.27 14 Y 
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CT570 6 0.001 -0.75 14 0.44  Y 
CT579 8 0.001 -2.15  0.03  Y 
CT584 0 0.000 NA  0.18  Y 
CT592 11 0.001 -1.83  0.00  Y 
CT642 20 0.005 -2.47  0.59  N 
CT664 7 0.001 -1.41  0.59  N 
CT668 6 0.002 -1.58  0.52  N 
CT694 14 0.003 -2.21  0.31 13 N 
CT695 7 0.001 -0.77  -6.89 14 N 
CT703 3 < 0.001 -1.62  -2.56  N 
CT728 2 0.001 -1.38  0.48  N 
CT764 2 < 0.001 -1.38  0.42  N 
CT795 1 < 0.001 0.24  0.04  N 
CT806 12 0.001 -1.83  0.20 5 N 
CT813 2 < 0.001 -0.52  0.67  N 
CT841 7 0.001 -1.10  0.22  N 
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CT875 9 0.001 -1.27  -0.09  N 
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Supplementary Table 4: Microarray raw signal intensity data (provided as individual file). 
Supplementary Table 5: EBI-ENA accession numbers for raw read data from sequenced Ct 
isolates. 
Supplementary Methods 
Clinical cohort study and participants 
In 2002 a rapid assessment survey of adults and children was carried out in the Western and 
North Bank Regions of The Gambia and villages with greater than 20 % prevalence of active 
trachoma (TF and/or TI) were selected 27,28. The study was designed to measure time to 
resolution and time to acquisition of infection and disease. Based on census data and previous 
studies on the household pattern of disease we expected 100 diseased subjects and 150 non-
diseased subjects at baseline, with > 80 % power to detect an adverse factor that doubles 
median infection/disease time in survival analysis.  A further three villages were included to 
increase the power of study as the prevalence of active trachoma in the target population 
(children aged four to fifteen years old) was lower than expected. The joint Gambian 
Government-Medical Research Council Ethics Committee and the Ethics Committee of the 
London School of Hygiene & Tropical Medicine approved the design and procedures of this 
study. 
School-age children in these villages were examined for the clinical signs of 
trachoma. A subset of 345 children between the ages of four and fifteen years old were 
recruited from households with a case of active trachoma and followed for a period of 28 
weeks. At baseline and approximately fortnightly visits (ten to nineteen days), children were 
examined for signs of active trachoma. Two swabs were collected, one into a dry 
polypropylene tube and the other into RNAlater™. Tear fluid was collected from the right 
eye using a sponge-tipped eye spear (Merocel®, Xomed Surgical Products, Jacksonville, FL, 
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USA), inserted in the inferior conjunctival fornix and held there for approximately 30 
seconds. Participants from one village withdrew consent en masse, after eight weeks. The 
completeness of follow-up was further influenced by individuals being absent from the 
village on visit days or travelling out of the area for the remainder of the study period 29. An 
episode of infection was defined as a positive result from an in-house 16S rRNA PCR 30, 
clinical disease was defined according the WHO simplified grading system 31. A subgroup of 
135 participants consented to venipuncture at the beginning of the study and 105 at cessation 
of the study. Collectively, 130 serum samples from baseline and cessation of the study were 
available for testing. 
For the classification of clinical categories and further analysis an episode of infection 
was defined as a Ct-positive result from an in-house 16S RNA RT-qPCR assay 30, an episode 
of disease was defined as presence of either follicular trachoma (TF) or inflammatory 
trachoma (TI) 31. An episode was considered continuous if an individual’s infection or 
disease status was consistent in consecutive visits, where data was missing between visits 
with inconsistent infection or disease status it was assumed status changed at the midpoint. 
Chlamydia trachomatis antigen microarrays 
Ct protein microarray chips were prepared as described previously 32 by Antigen Discovery 
(Irvine, CA) and screened using sera from 123 patients. Briefly 894 ORFs from the Ct 
D/UW3-CW genome were PCR amplified and in vivo cloned into the pXT7 expression 
vector which expresses proteins with an N-terminal His fragment and a C-terminal 
haemagglutinin sequence and T7 terminator. Ct-specific products were expressed from the 
plasmids using an in vitro transcription translation system (RTS 100 kit, Roche Diagnostics, 
West Sussex, UK) and printed on nitrocellulose coated glass slides (GraceBio, Bend, OR, 
USA) using an OmniGrid Accent microarray printer (Digilab, Marlborough, MA, USA). 
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Successful expression of the proteins was determined using antibodies against His (clone His-
1; Sigma) and haemagglutinin (clone 3F10; Roche Diagnostics, West Sussex, UK). 
 Prior to testing sera was diluted 1/100 in blocking buffer (10 % Escherichia coli 
lysate [McLab, San Francisco, CA, USA] in protein array blocking buffer [Whatman, 
Piscataway, NJ, USA]) at room temperature for 30 minutes with agitation while the 
microarrays were rehydrated using protein array blocking buffer (Whatman, Piscataway, NJ, 
USA). The arrays were interrogated with sera at room temperature for 2 hours with agitation. 
After 3 washes with washing buffer (0.05 % Triton X-100 in phosphate-buffered saline (PBS) 
at pH 7.5) the microarrays were incubated with biotin-conjugated goat anti-human antibody 
(Jackson ImmunoResearch Laboratories, West Grove, PA, USA). After 3 washes the 
microarrays were incubated with streptavidin-conjugated Sensilight P3 (Columbia 
Biosciences, Columbia, MD, USA). The microarrays were scanned using a ScanArray 
Express HT microarray scanner (Perkin Elmer, Waltham, MA, USA) and the fluorescence 
signal was quantified and corrected for background noise using QuantArray software (Perkin 
Elmer, Waltham, MA, USA). 
Proteome microarray normalisation, filtering and clustering 
The raw signal intensity data from the microarray was transformed by inverse hyperbolic sine 
transformation and normalised by mean-centring, these techniques were determined as the 
most suitable ‘normalisation’ step using relevant rank deviation (RRD) 33. Post-normalisation 
the global median of the data was calculated, individual antigens whose median was lower 
than the global median were excluded.  
 Several different methods were tested to identify positive-negative breakpoints in the 
distribution of the data. We tested extrinsic and intrinsic methods. Extrinsic methods tested 
were; mean of no DNA controls, global mean and global mean plus 2 standard deviations. 
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Intrinsic methods tested were; k-means clustering, k-medoids clustering, fuzzy c-means 
clustering, hierarchical clustering and mixture modelling. The intrinsic methods were tested 
allowing for 2 to10 clusters. The average silhouette width of each antigen was used to 
determine appropriateness of the cluster configuration. Silhouette ranges from -1 to +1 and is 
defined by equation 1.  
 
 
 
(1) 
Where i is a data point, a is average dissimilarity with all other data points in its cluster, b is 
the lowest average dissimilarity to any other cluster of which i is not a member. If i is similar 
to other data in its cluster a will be low. If i is also dissimilar to data in the nearest cluster b 
will be high. In this case silhouette will tend towards +1. If i is not similar to its cluster a will 
be high. If i is similar to data in the nearest cluster b will be low. In this case silhouette will 
tend towards -1. 
The mean of each silhouette per antigen resulted in the average silhouette width, 
which was a measure of the appropriateness of the cluster configuration. To determine 
positive responses, two clusters were identified and the method which had the highest 
average silhouette width for each antigen was identified. Data points clustered with the 
maximum OD/signal intensity point of each antigen were considered positive and the 
opposing cluster negative. 
Diversity metrics 
Ecological measures of diversity rely on species breadth/richness, the total number of species 
in a sample, and species diversity, which additionally incorporates the relative abundance of 
each species. In this analysis antigens were considered as species, abundance as the response 
to each antigen and the samples were either the complete data set or split into the 
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dichotomous outcome variables. These definitions are based on the assumption that responses 
on the array correlate with abundance of circulating antibodies in each sample. A normalised 
OD of 1 unit was interpreted as 1 arbitrary unit of circulating antibody. This means if a 
response to an antigen is twice the level in one sample compared with another, circulating 
antibodies are twice as abundant in that individual.  
Breadth was defined as the number of antigens to which each individual made a 
positive response. For the remaining measures examining diversity existing methods were 
adapted to incorporate the continuous OD/signal intensity values. This was deemed more 
appropriate as an assumption of these methods was that individuals within a species are 
equivalent 34,35, in this analysis the species are antigens and positive responses within them 
are not equal.  
 We utilised two different measures of diversity to improve reliability of the results. 
Shannon’s entropy (H) defined by equation 2, Simpson’s index (D) defined by equation 3 and 
Hill numbers defined by equation 4 35. Higher values for all three indicate increased diversity 
and greater evenness. High values of H mean 1 unit of antibody in a sample could be targeted 
against any antigen because responses in the sample are even 36. High values of D mean that 
2 separate units of antibody from the array they are unlikely to be targeted against the same 
antigen due to evenness of the responses 36. 
 
 
 
 
(2) 
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(3) 
Where S is number of antigens and pi is the proportion of antibodies specific to each antigen. 
Pi is estimated as the amount of antibody specific to each antigen divided by the total amount 
of antibody present in each individual. 
Chlamydia trachomatis population genetics metrics 
Survey, clinical examination and sample collection methods have been described 
previously37. Briefly, we conducted a cross-sectional population-based survey in trachoma-
endemic communities on the Bijagós Archipelago of Guinea Bissau. Conjunctival swabs 
were obtained from the left upper tarsal conjunctiva of each participant, DNA was extracted 
and Ct omcB (genomic) copies/swab quantified from the second conjunctival swab using 
droplet digital PCR (ddPCR) 38.  
For 8 individuals, whole genome sequence (WGS) data was obtained following Ct 
isolation in cell culture. For the remaining individuals (118), WGS data were obtained 
directly from clinical samples. DNA baits spanning the length of the Ct genome were 
compiled by SureDesign and synthesized by SureSelectXT (Agilent Technologies, Santa 
Clara, CA, USA). Ct DNA extract from clinical samples was quantified and carrier human 
genomic DNA added to obtain a total of 3µg input for library preparation. DNA was sheared 
using a Covaris E210 acoustic focusing unit 39. End-repair, non-templated addition of 3’–A 
adapter ligation, hybridisation, enrichment PCR and all post- reaction clean-up steps were 
performed according to the SureSelectXT Illumina Paired-End Sequencing Library protocol 
(V1.4.1 Sept 2012). All recommended quality control measures were performed between 
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steps. DNA was sequenced at the Wellcome Trust Sanger Institute using Illumina paired-end 
technology (Illumina GAII or HiSeq 2000). All 126 sequences passed standard FastQC 
quality control criteria 40. Sequence data is available from the European Bioinformatics 
Institute (EBI) short read archive (Supplementary Table 3). 
Alignment, assembly and filtering by individual genes 
Raw fastq files were aligned and assembled using BWA SAMtools 41 with A/Har-13 as the 
reference genome. Variants were called and filtered using BCFtools 42 and VCFtools 43, with 
a minimum base quality score of 20 (99% accuracy) and a minimum read depth of 10.  
Assembled sequences were combined and used as a database in the command-line 
version of Basic Local Alignment Search Tool (BLAST+)44. Individual gene sequences from 
A/Har-13 were used as queries to extract copies successfully sequenced in the isolates. 
Sequences with more than half missing calls were excluded. MUSCLE algorithm was used 
for gene alignments 45. Alignments were inspected manually using SeaView 46 and 
visualisation were output using Geneious 47. 
Allele frequency-based signatures of selection 
Aligned multi-fasta files for each gene were used as input for Variscan-2.0.3 48 to calculate 
Tajima’s D, Fu and Li’s D* and F* and Fay and Wu’s H. RunMode 12 and RunMode 22 
were used, sites with less than 50 sequences were not included. Sliding-window analyses 
were performed over windows of 42 nucleotides with jumps of three nucleotides. All three 
measures look at the number and frequency of mutations within a population to determine 
whether they occurred randomly under neutrality or were caused by a form of natural 
selection. They are based on different methods of estimating the genetic diversity (θ) in a 
population 49. 
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Tajima’s D compares the average pairwise diversity (π), the average difference 
between a pair of sequences across all sites, and the number of segregating sites (κ), the 
number of sites within a population which are polymorphic 50. Tajima’s D is calculated from 
equation 7. For equation 5, x is the frequency of sequences i and j, δ is the number of 
nucleotide differences per site between them and N is the total number of sequences. For 
equation 6, n is the number of sequences and i is the number of times a given allele is present. 
 
 
(5) 
 
 
(6) 
 
 
(7) 
 
Positive selection increases the frequency of a few advantageous mutations, meaning most 
mutations are kept at a low frequency. In this situation the average difference between pairs 
of sequences is low but the number of segregating sites is relatively high, thus D is negative. 
Purifying selection reduces the frequency of deleterious mutations, meaning mutations occur 
but not become common. In this situation the average difference between pairs of sequences 
is low and the number of segregating sites is high, thus D is negative. Balancing selection 
maintains multiple mutations at intermediate frequencies, this results in increased 
polymorphism at these sites. In this situation the average difference between pairs of 
sequences is higher but the number of segregating sites remains stable, thus D is positive. A 
limitation of Tajima’s D is the influence of population changes. Population expansion will 
increase the number of low frequency mutations making D negative, population bottlenecks 
will reduce the number of low frequency mutations making D less negative. 
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Fay and Wu’s H can be used to determine which form of natural selection is 
occurring, or more accurately which is the dominant selection pressure. Fay and Wu’s H 
utilises an outgroup sequence (A/Har-13) and focusses on the difference between 
intermediate and high frequency alleles rather than intermediate and low frequency alleles 51. 
H is calculated from equation 9. Where n is the number of sequences, i is the number of times 
an allele occurs and ξi is the number of differences from the ancestral outgroup per allele. 
  
 
(8) 
  
 
(9) 
  
 
(10) 
 
H is heavily influenced by high frequency alleles because of the i2 component in equation 9. 
Purifying selection keeps alleles from becoming common, therefore are few high frequency 
alleles and H is positive. Positive selection causes alleles to rise to fixation and thus increase 
in frequency, in these situations H is negative.  
Haplotype-based signatures of selection 
These metrics utilising allele frequencies were complemented by a haplotype based method, 
the integrated haplotype score (iHS). iHS identifies alleles at intermediate frequencies that 
are being driven towards fixation (positive selection) or under balancing selection 52. 
Extended haplotype homozygosity (EHH) is a measure of distance calculated around SNPs 
on a given haplotype, if the haplotype is all the same EHH will be 1 and if it is all different 
EHH will be 0. Integrated haplotype homozygosity (iHH) is calculated as the decrease or 
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decay in EHH with genetic distance from a given SNP, both on the ancestral sequence and 
the derived sequence. In our studies the ancestral allele was defined as the allele in A/Har-13 
and the derived allele was defined by variants in the Ct isolates from Guinea-Bissau. The 
unstandardised iHS is calculated from equation 13. Where iHHA and iHHD are the iHH from 
the ancestral and derived sequences respectively. 
 
 
(13) 
  
Unstandardised iHS is then standardised based on the genome-wide mean and variance of 
iHS for SNPs with the same allele frequency. If multiple SNPs with evidence of selection are 
within a defined distance of each other, EHH greater than 0.05, they can be combined to 
indicate windows under selection. Values significantly <1 indicate longer haplotypes on the 
derived sequence, indicative of a selective sweep driving an allele towards fixation before 
further mutations have arisen. Values significantly > 1 indicate longer haplotypes in the 
ancestral sequence, which is a sign of selection. Selection could now be favouring the 
ancestral allele or ancestral alleles around the favoured site could be hitchhiking. In our 
analysis we used the absolute iHS, classifying significantly positive values as indicators of 
selection. 
 Short read data from the 126 ocular Ct samples were mapped against Ct A/HAR-13 
using SAMtools 17. Non-polymorphic sites were removed. SNPs with a minor allele 
frequency (MAF) less than 0.05 and more than 25 % missing calls were excluded. Alleles 
were defined as ancestral (0) or derived (1) based on the ancestral isolate A/Har-13. iHS 
cannot be calculated over sites with missing base-calls, for this reason imputation was used to 
classify missing base-calls. A simple genetic distance-based imputation was used. Genome-
wide pairwise nucleotide diversity was calculated for each pair of sequences. For each 
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missing base-call within a sequence, all sequences with base-calls at those sites were assigned 
a score based on the pairwise diversity between them and the sequence with a missing base-
call. These scores were summed at each site for ancestral and derived base-calls respectively 
and divided by the number of respective base-calls. The state with the lower score was used 
to define the missing base-call. iHS was calculated using the R package rehh, Scores were 
standardised as described above after binning MAF into 40 discrete bins of size 0.025 [0.000-
0.025, 0.025-0.05,..…,0.950-1.000]. 
Molecular and functional characterisation of target genes and proteins 
Developmental cycle expression stage for each transcript was based on data and groupings 
from Belland et al16, this grouping was manually assigned to data from Nicholson et al53. 
Localisation of expressed proteins was predicted using Cello54, pSORTB55 and loctree356, 
three of the top performing servers for bacterial proteins56. Predicted localisation was defined 
as the consensus from the 3 predictions. Immunogenicity and function were determined 
through a PubMed literature search with three terms; “CT_xxx”, “CTA_xxxx” and 
“Chlamydia trachomatis”. Similarly, expression stage and localisation predictions were 
validated through a PubMed literature search, for evidence of expression determined by RT-
qPCR and localisation determined by microscopy or immunoblotting. 
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